News Alkermes may separate oncology business, says CEO Alkermes has said it is considering a spin-out of its cancer business into an independent, publicly-traded company, retaining its traditional focus on neurosciences.
News Pfizer’s CNS exit takes the form of a biotech spinout Pfizer’s plans to duck out of central nervous system R&D have come to fruition, with the creation of spinout biotech Cerevel Therapeutics.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.